1	
2	
3	
4	
5	Discrimination of Primary and Chronic CMV Infection based on Humoral Immune Profiles in Pregnancy
6	
7	
8	
9	Andrew P. Hederman ¹ , Christopher J. Remmel ¹ , Shilpee Sharma ² , Harini Natarajan ³ , Joshua A. Weiner ¹ ,
10	Daniel Wrapp ⁴ , Catherine Donner ⁵ , Marie-Luce Delforge ⁶ , Piera d'Angelo ⁷ , Milena Furione ⁷ , Chiara
11	Fornara ^{7,8} , Jason S. McLellan ⁴ , Daniele Lilleri ⁷ , Arnaud Marchant ² , Margaret E. Ackerman ^{1,3} #
12	
13	
14	
15	
16	¹ Thayer School of Engineering, Dartmouth College, Hanover, NH, USA
17	² European Plotkin Institute for Vaccinology, Université libre de Bruxelles, Brussels, Belgium
18	³ Department of Microbiology and Immunology, Geisel School of Medicine, Hanover, NH, USA
19	⁴ Department of Molecular Biosciences, The University of Texas, Austin, TX, USA
20	⁵ Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B.), CUB Hôpital Erasme,
21	Department of Obstetrics and Gynecology, Brussels, Belgium
22	⁶ Université Libre de Bruxelles (ULB), Hôpital Universitaire de Bruxelles (H.U.B.), CUB Hôpital Erasme,
23	National Reference Center for Congenital Infections, Brussels, Belgium
24	⁷ Microbiology and Virology, Fondazione IRCCS Policlinico San Matteo, 27100 Pavia, Italy
25	⁸ Current affiliation: General Clinical Laboratory, with specialist areas of Clinical Pathology, Microbiology
26	and Virology, Istituti Clinici Scientifici Maugeri IRCCS, 27100 Pavia, Italy
27	
28	
29	
30	# Corresponding Author
31	Margaret E. Ackerman
32	14 Engineering Drive
33	Hanover, NH 03755
34	margaret.e.ackerman@dartmouth.edu
35	(ph) 603 646 9922
36	(fax) 603 646 3856

37 Abstract

38 Most humans have been infected by Cytomegalovirus (CMV) by the time they reach forty years of 39 age. Whereas most of these CMV infections are well controlled by the immune system, congenital 40 infection can lead to serious health effects and death for the fetus and neonate. With clear evidence that 41 risk to the fetus is lower during chronic maternal infection, and varies in association with gestational age 42 at the time of primary maternal infection, further research on humoral immune responses to primary CMV 43 infection during pregnancy is needed. Here, systems serology tools were applied to characterize antibody 44 responses to CMV infection among pregnant and non-pregnant women experiencing either primary or 45 chronic infection. Whereas strikingly different antibody profiles were observed depending on infection 46 status, more limited differences were associated with pregnancy status. Beyond known differences in IgM 47 responses that are used clinically for identification of primary infection, distinctions observed in IgA and FcyR binding antibody responses and among viral antigen specificities accurately predicted infection 48 49 status in a cross-sectional cohort. Leveraging machine learning, longitudinal samples were also used to 50 define an immunological clock of CMV infection from primary to chronic states and predict time since 51 primary infection with high accuracy. Humoral responses diverged over time in an antigen-specific 52 manner, with IgG3 responses toward tegument decreasing over time as is typical of viral infections, while 53 those directed to pentamer and glycoprotein B were lower during acute and greatest during chronic 54 infection. In sum, this work provides new insights into the antibody response associated with CMV 55 infection status in the context of pregnancy, revealing aspects of humoral immunity that have the potential 56 to improve CMV diagnostics and to support clinical trials of interventions to reduce mother-to-fetus

57 transmission of CMV.

58 Introduction:

59 A member of the herpesvirus family, human cytomegalovirus (CMV) commonly manifests as a 60 mild or asymptomatic infection. However, in very young and immunocompromised individuals, CMV can cause severe disease; it is the leading cause of congenital infection among newborns¹. In the United 61 62 States alone it is estimated that 40,000 children are born with congenital CMV (cCMV) infection every 63 year¹. This high burden is still likely an underestimate since many cases are asymptomatic at birth. Many 64 of the diagnosed infections are severe, leading to an estimated 400 deaths and an additional 8,000 cases 65 presenting with permanent disabilities, including speech and language impairment, hearing loss, mental disability, cerebral palsy, and vision impairment, annually^{1,2}. Fetal infection results from intrauterine 66 transmission and is most likely to occur when a mother experiences primary CMV infection during 67 68 pregnancy^{3,4}. The difference in fetal infection risk between primary and reactivated maternal CMV infection is striking, with approximately one third of primary infections leading to CMV infection of the fetus 69 as compared to < 3.5% estimated to result from CMV reactivation or superinfection⁵⁻⁹. New insights into 70 71 CMV infection during pregnancy that could contribute to identification of pregnancies at greatest risk, and 72 efficient testing of new therapeutic interventions are urgently needed¹⁰. 73 Pregnant women present a population of subjects who are not immunodeficient, but in a unique 74 state of immune regulation in order to ensure fetal tolerance, and can transmit CMV to their fetus during 75 pregnancy. While the differing risk of transmission associated with maternal seropositivity provides strong 76 evidence that pre-conception immunity plays a protective role, studies evaluating the clinical potential of CMV-hyperimmune globulin to improve neonatal outcomes have yielded mixed results¹¹⁻¹³. It has been 77 78 speculated that these differing outcomes may relate to gestational age and the timing of the intervention 79 following maternal infection and therefore be impacted by both the reliability of the diagnostic approach

and strictness in the definition of primary infection cases. Because the suitability of these approaches for

81 application during pregnancy can be supported by comparison of responses in pregnant with non-

82 pregnant individuals during primary infection, developing a deeper understanding of humoral immune

profiles in this unique immune state may have implications for the clinical development of diverse small
 molecule and biologic antiviral interventions.

85 Short of these goals, given the widely diverging congenital infection risks associated with primary 86 and chronic infection, confident discrimination between these two states is crucial for identifying newborns 87 with highest risk of cCMV infection. Complementing virological assessment, discrimination of these two 88 states using serology may allow antiviral treatment in pregnant women and hearing and learning interventions in newborns to be initiated early^{14,15}. Current diagnostic assays for pregnant women are 89 performed using serology measurements for IgM and IgG avidity, while a PCR based urine test, often 90 following a saliva PCR screening test, is the standard for newborns^{14,16-18}. However, although CMV is a 91 92 common infection, there is no universal standard diagnostic assay across countries and healthcare centers¹⁹, introducing variability in care and posing challenges to clinical trial design for testing of novel 93 94 interventions. Additionally, many countries, including the United States, do not routinely screen for CMV

95 in pregnant women, whereas some European countries do perform routine screening, adding another

96 layer of complexity into clinical data regarding the impact of maternal CMV status, antibody responses,

97 and timing of infection as assessed by differing diagnostic measures and across populations. Irrespective

- 98 of these details, following a primary CMV diagnosis during pregnancy, clinicians typically counsel
- 99 pregnant women about the future risks to their fetus.

100 The dichotomy in fetal risk profiles of primary and non-primary CMV infection has important 101 implications in transmission risk for pregnant women. Beyond this classification, the specific timing of

- 102 CMV infection is also a crucial factor in potential of severe congenital disease, with a primary infection in
- 103 the first term of pregnancy leading to higher likelihood of severe cCMV infections as compared to a
- 104 primary infection in the second or third trimester ²⁰. Further insights into relative risk profiles are

105 challenged by imperfect precision in defining and estimating the timing of primary infection, particularly

- 106 during pregnancy, which has been associated with varying and dynamic immunological state changes²¹.
- 107 As a result, more accurate and confident diagnosis of primary and non-primary CMV infection would
- 108 benefit the medical community and affected birthing parents by providing clearer and more definitive
- 109 insights into their CMV infection status and associated risk to the fetus.

110 However, previous work in a variety of infectious disease settings has shown that antibody responses evolve over time, exhibiting complex patterns in response magnitude and characteristics²²⁻²⁴. 111 and that they can also differ in association with pregnancy²⁴⁻²⁶. Pregnant women with primary CMV 112 113 infection represent a unique intersection of these two complex antibody response scenarios with 114 established clinical significance. Here, leveraging machine learning and highly multiplexed assays to 115 capture a wide range of antibody response attributes over time, we evaluate how responses to primary or 116 non-primary CMV infection during pregnancy and over time may vary, providing insight into the role 117 pregnancy may play in modifying these responses and new means of predicting and reducing risk of 118 cCMV infection for affected pregnancies.

119

120 Results

121 Antibody Profiles Distinguish Primary from Chronic CMV Infection

Antibody responses were profiled among both pregnant and non-pregnant individuals with either primary or chronic CMV infection (**Table 1**), with primary infection strictly defined by CMV-specific IgG seroconversion, CMV-specific IgM antibody detection, low IgG avidity index, and/or CMV DNAemia. Conversely, chronic infection was defined by seropositivity in the absence of these diagnostic measures. To more comprehensively understand how antibody profiles vary among pregnant primary (n=114), nonpregnant primary (n=29), pregnant chronic (n=30), non-pregnant chronic (n=30) CMV-infected individuals, in addition to naïve subjects (n=9), antibodies specific for CMV tegument protein²⁷ (CG1 and CG2),

- 129 glycoprotein B (gB), and the pentamer complex were characterized for isotype, subclass, and Fc
- 130 Receptor (FcR) binding capacity (**Supplemental Figure 1, Supplemental Table 1**). We profiled the
- 131 antibody response examining a diverse set of antibody features and CMV antigens, including gB and

pentamer complexes from several different sources, with the aim of gaining a more holistic view of the
humoral immune response to primary or chronic CMV infection. Glycoproteins tested included several
that are commercially available (Sino (Sino Biologicals), and NA (Native Antigen)), as well as others that
have been characterized in structural studies conducted with an eye toward vaccine development
(GSK)^{28,29}, and by academic groups (UT)^{30,31}, including a novel modified form of gB with engineered
proline mutations (3p).

138 To define differences in antibody profiles among subject groups that go beyond the measures 139 typically used in clinical diagnosis, we performed UMAP analysis on CMV-specific antibody features 140 excluding IgM (Figure 1A). This unsupervised analysis revealed that the main aspects of differentiation 141 among subjects related to infection status; strong distinctions in the antibody response were observed 142 between individuals with primary as opposed to chronic infection. In contrast, limited differences in the 143 global response profiles were observed between pregnant and non-pregnant individuals. While univariate 144 analysis between pregnant and non-pregnant individuals did reveal some nominally statistically significant 145 differences across or within primary and chronic infection groups (Supplemental Figure 2), we could not 146 exclude the possibility that these differences resulted from a difference in timing of diagnosis or were 147 impacted by differences in age between cohorts. The former may be likely, as similarly subtle differences 148 were observed between primary subjects in these groups and another cohort (Erasme Hospital) of 149 pregnant women with primary CMV infection (Supplemental Figure 3). Given these observations and the 150 lack of robust differences associated with pregnancy status, this variable was not considered in 151 subsequent analyses.

152 We next investigated which individual features of the immune response might contribute to 153 clustering of subjects in primary and chronic infection groups. Visualizing the degree and confidence of 154 differences in antibody response features between primary and chronic infection status groups revealed 155 aspects of the humoral response that consistently differed (Figure 1B-C). Distinct levels of CMV-specific 156 IgA, IgM, and FcR binding antibodies were observed between primary and chronic infection groups 157 across multiple CMV antigens. IgM responses were elevated across all antigens for the primary infection 158 group, which was expected as IgM titers were used to define infection status. Interestingly, total CMV-159 specific IgA and both IgA1 and IgA2 subclasses were elevated in primary infection subjects. Somewhat 160 surprisingly, total IgG had very modest differences between primary and chronic infection groups. 161 Given the striking differences among groups we next wanted to further examine individual 162 responses for IgM, IgA, and IgG across the panel of CMV antigens. As expected, IgM responses were 163 strongly and significantly elevated among subjects with primary infection, as were IgA responses across

diverse antigen specificities (**Figure 1C**). Interestingly, and in contrast with total IgG response levels

165 (Figure 1C), which exhibited statistically significant but relatively small differences in response

166 magnitude, FcyR-binding antibodies were both significantly and strongly elevated among subjects with

167 chronic CMV infection (Figure 1B, Supplemental Figure 4), suggesting the presence of qualitative

168 differences in the antibodies present during primary and chronic infection.

169

170 IgG Subclasses and CMV Antigens Display Distinct Profiles in Primary and Chronic Infection

171 The observation that FcyR binding antibodies but not total IgG were reliably elevated in chronic 172 subjects was intriguing, and suggested that differences in induction of IgG subclasses, which differ 173 dramatically in their FcR binding capacity, may exist. However, with the exception of IgG2 responses to 174 tegument, IgG2 and IgG4 responses to CMV antigens were uncommon, and therefore differences in the 175 levels of these more functionally inert subclasses were not observed (Supplemental Figure 5). Humoral 176 responses to viral infections are generally dominated by IgG1 and IgG3 antibodies, which both bind well 177 to activating FcyR and have the potential to elicit the potent antiviral activities of the complement cascade and innate immune effector cells. While statistically significant differences were observed for a subset of 178 antigens tested, IgG1 responses, which are typically dominant following acute viral infections^{32,33}, were 179 180 generally similar in primary and chronic infection (Figure 2A). Only one of each of the gB, pentamer, and 181 tegument proteins tested showed a statistically significant difference, and each of these demonstrated 182 only a small increase among the chronic infection group. In contrast, IgG3 responses were more 183 uniformly and strikingly distinct between groups. Perhaps most surprisingly, the direction of these 184 differences varied by antigen-specificity. Antibody responses to tegument proteins exhibited elevated 185 levels in primary infection, but elevated levels of gB and pentamer-specific IgG3 were observed among 186 the chronic infection group (Figure 2A). While all pentamer complexes tested showed this profile, 187 responses to recombinant gB proteins were more variable, with two gB preparations showing elevated 188 levels among chronic subjects, and one preparation showing elevated levels in primary infection. While 189 some distinctions in IgG subclass composition in the context of primary and latent herpesvirus infections have been reported³⁴⁻³⁸, how well they may support discrimination between primary and chronic CMV 190 191 infection is not known. In sum, while IgG1 responses tended to either persist or increase between primary 192 and latent infection classes, IgG3 responses differed dramatically by antigen-specificity; responses to 193 tegument were higher among subjects with primary infection, but responses to gB and pentamer were 194 instead elevated in chronic infection.

195 While UT pentamer-specific IgG1 and IgG3 levels were correlated with each other among subjects with primary infection (R_P=0.33, p<0.0001), they were not well correlated among individuals with 196 197 chronic infection ($R_P=0.20$, p=0.08). This difference in degree of correlation between IgG1 and IgG3 198 responses between infection status states was consistent across pentamer proteins evaluated. 199 Additionally, the strength of correlation observed between these IgG subclasses and the FcyRIIIaV-200 binding capacity of pentamer-specific antibodies changed over time, with stronger correlations between 201 IgG1 and FcyRIIIaV observed in primary infection, but IgG3 and FcyRIIIaV binding in chronic infection 202 (**Figure 2C**). These patterns were consistent across $Fc\gamma Rs$ and pentamer proteins tested (**Figure 2D**), 203 suggesting that the pool of antibodies most capable of eliciting FcyR-dependent effector functions 204 changes in composition over the course of infection. These temporal differences may have important 205 implications to viral pathogenesis and host defense.

206

207 Prediction of CMV infection status using machine learning

208 Next, because unsupervised analysis of antibody profiles revealed clear distinctions between 209 primary and chronic CMV infection, we applied supervised machine learning to explore the ability of a 210 model to accurately discriminate primary and chronic CMV infection (Figure 3A). We employed a logistic 211 regression framework with regularization to classify primary or chronic CMV infection based on antibody 212 profiling data while reducing the risk of overfitting associated with high-dimensional data. Again, IgM 213 responses were excluded because they were used in clinical class assignment of the study groups. The 214 model was trained on 80% of primary and chronic subject profiles while the remaining 20% was used for 215 testing. Furthermore, repeated five-fold cross validation was employed so each subject would be part of 216 the test set and representative accuracy across different folds could be defined. 217 Model predictions were highly accurate; across 100 repeated five-fold cross validation runs, the 218 median model accuracy for predicting primary or chronic CMV infection was 94% (Figure 3B). In contrast, 219 prediction results were essentially random when training and testing was performed after permutation of 220 class labels, which serves as a means to assess model robustness by measuring the potential for 221 overfitting. Misclassifications were not biased toward one or the other class, as shown for the cross 222 validation run repeat presenting median accuracy as a representative confusion matrix (Figure 3C). 223 Classification calls for actual but not permuted class labels were both typically correct and assigned to 224 respective classes with high probability (Figure 3D). The relatively few incorrect classifications were 225 typically close to the decision boundary. Given this evidence of model accuracy and robustness, a final 226 model was trained on all subjects in the discovery cohort. When applied to an independent set of 57 227 primary infection and 40 chronic infection samples serving as a validation cohort, this model resulted in 228 similarly high confidence and perfect classification accuracy (Figure 3D). Given this validation, the top 229 features employed in the final model were examined (Figure 3E). The features with largest positive 230 coefficients, which serve to identify primary subjects, were primarily IgA-related antibody responses 231 directed to tegument antigens (4/5 features). Conversely, features with large negative coefficients, useful 232 to identify chronic infection, were typically related to IgG3 and FcyRIII-binding capacity of response to gB 233 and pentamer (4/5 features). Collectively, these modeling results point to novel antibody response

- 234 attributes, distinct from traditionally considered parameters such as IgM and IgG avidity, as being
- 235 excellent candidate markers for distinguishing primary and chronic infection status.
- 236
- 237

Modeling Longitudinal Responses to CMV Infection Reveals a Molecular Clock of Antibody Responses

238 The excellent discrimination of primary and chronic CMV infection in the validation cohort led us 239 to next explore how class predictions related to longitudinal development of humoral immune responses 240 to infection. To this end, subsequent samples were available for the validation cohort over a series of up 241 to four visits that extended out to half a year after initial sampling or infection onset. The model trained on 242 the initial cohort was used to predict class for longitudinal samples from the validation cohort (Figure 4A).

243 Whereas chronic subjects were consistently classified as such with similarly high confidence at all 244 subsequent visits, subjects with primary infection at the initial timepoint became less confidently classified 245 as primary at subsequent visits (Figure 4B). By visit four, the majority of samples from subjects with 246 primary infection at their initial visit exhibited class probabilities below the lowest observed at the initial 247 sampling. However, because visits were not consistently spaced in time between subjects, these 248 longitudinal profiles can be more meaningfully compared over time post symptom onset (Figure 4C). 249 Despite the imperfect reliability of projected timing of infection, the classification model probabilities 250 presented a clear relationship with time. Samples fell below the midpoint on the classification scale as 251 early as 90 days post infection onset, but failed to reach values typically observed among chronic 252 subjects even out at 250 days post infection, suggesting a relatively prolonged transition to reaching the 253 chronic state profile. As expected, the individual antibody response features making the greatest 254 contributions to the classification model also demonstrated clear changes among subjects with primary, 255 but not chronic infection, over time (Figure 4D). 256 To this point, machine learning models have only been concerned with making predictions on the

257 probability of a sample belonging to either the primary or chronic infection class. However, given the clear 258 ability for these binary classification models to provide insight into time since infection, we next sought to 259 evaluate models explicitly trained for this specific purpose. For this purpose, longitudinal profiles of the 260 primary infection cases across visits were used to train a model to predict time since symptom onset as a 261 continuous variable (Figure 4E). The resulting linear regression model, which showed good robustness in 262 the context of five-fold cross-validation (Supplemental Figure 6A), was then used to predict days post 263 infection for the cross-sectional primary samples. This model, which relied primarily on IgG3 features 264 (Supplemental Figure 6B) showing strong time-dependence (Supplemental Figure 6C), was then 265 applied to the cross-sectional cohort. Predictions of time since symptom onset in the unseen validation 266 cohort exhibited excellent accuracy (Figure 4F). Overall, this analysis demonstrated that antibody profiles 267 in CMV-infected individuals exhibit generalizable temporal patterns in their dynamic antibody responses 268 during primary infection.

269

270 Discussion

271 Presently, discrimination of primary and non-primary CMV infection in the context of pregnancy is 272 used in counseling as to the risk of congenital CMV infection based on the lower risk of congenital 273 infection associated with non-primary infection and the prescription of antiviral therapies. Beyond this 274 value, in the absence of an effective vaccine, a deeper understanding of how immune responses differ in 275 association with transmission risk has the potential to contribute to the development of new interventions. 276 Here, high dimensional antibody profiles beyond IgM levels and IgG avidity were developed from a 277 commonly used multiplex assay format and supervised and unsupervised machine learning was used to 278 differentiate primary and chronic infection and pregnancy status.

279 Whereas limited or no differences in humoral responses were associated with pregnancy status, 280 our study showed clear distinctions in antibody profiles between primary and chronic infection cases. Both 281 composite profiles individual antibody features related to antigen-specificity and immunoglobulin isotype, 282 subclass, and binding to Fc receptors demonstrated these distinctions. Importantly, these differences 283 extended beyond those previously known to exist and which are presently applied to support clinical 284 diagnosis. The number and longitudinal profiles of the features that distinguish infection history suggested 285 that a sort of humoral clock could be defined in order to time the onset of primary CMV infection. Indeed, 286 supervised machine learning models that reliably captured how antibody responses to CMV infection 287 varied over time were learned and validated on independent samples.

288 Beyond potential clinical utility, the defining features of how responses to primary CMV infection 289 transition over time is relevant to understanding the evolution of the immune response to this member of the notoriously immune-evasive Herpesviridae family^{39,40}. Current diagnostic methods rely on 290 291 detection/levels of IgM and of IgG avidity. The presence of IgM alone is insufficient to diagnose a primary CMV infection: poor correlation between commercial tests have been reported⁴¹, and false positive 292 293 primary status calls can result from both persistence of IgM as well as boosting in response to reactivation^{42,43}. Likewise, a positive test for CMV-specific IgG indicates an individual is positive for CMV 294 but provides little information into the time since infection^{14,44}. However, the combination of IaM positivity 295 296 and low IgG avidity is generally considered to be a reliable indicator of primary CMV infection, though 297 interpretation of IgG avidity tests are confounded by low levels of CMV-specific IgG, intermediate 298 responses raise classification issues, and these indicators are supported by clinical studies of small size. 299 Coupled to the lack of an international standard serum panel of samples from primary infection, the 300 difficulty inherent to establishing a uniform, accurate, and robust diagnostic method is clear⁴⁵. Our data 301 demonstrates that there are other changes in the secreted antibody repertoire that reliably occur over 302 consistent time periods during primary infection.

303 Prior studies of IgG subclasses of CMV-specific antibodies have consistently reported the IgG1 and IgG3 bias typical of anti-viral antibodies but noted that subclass responses and total IgG titers can be 304 discordant^{35,46}. Further, they have attributed relatively greater neutralization potency to this minor portion 305 to IgG3³⁶ To that end, we were surprised to observe increasing levels of IgG3 specific for viral 306 307 glycoproteins over time. Whereas IgG3 responses are usually associated with acute infections and typically wane over time^{33,47-49}, they were observed to increase across both cross-sectional and 308 309 longitudinal cohorts, but to do so in an antigen-specific manner. Namely, whereas IgG3 responses to 310 tegument proteins showed the typical pattern and decreased while IgG1 responses were stable or 311 increased, IgG3 responses to pentamer increased while IgG1 responses remained largely stable. 312 Memory B cells (MBC) specific for gB are known to exhibit phenotypic states distinct from those specific for tegument antigens⁵⁰. The reduced frequency of MBCs with effector potential specific for glycoprotein 313 314 as compared to tegument observed in this prior study may relate to the altered kinetics of IgG subclasses 315 observed here. While the mechanistic underpinning and the biological implications of this unusual pattern

have yet to be determined, CMV expresses two Fc binding proteins, gp34 and gp68⁵¹. Unlike the viral
 FcR of HSV, these proteins have been reported to bind to all human IgG subclasses^{52,53}, though affinities
 have not been reported. Additionally, how these two surface proteins contribute to viral pathogenesis is
 incompletely understood⁵⁴.

320 Limitations of this study include the fact that the majority of samples were sourced from a single 321 geographic region, leaving open the possibility that differences associated with host genetics and 322 environmental and infectious disease exposure history impact these observations. While relationships 323 between maternal immune responses and transmission of cCMV are of exceptionally high clinical 324 relevance, this study focused on CMV infection history. However, while risk is considerably greater during primary infection, there are certainly differences in virologic, innate immune, and other factors that 325 contribute to these differing risk profiles⁵⁵⁻⁵⁸. The influence of maternal antibody responses is unclear, 326 particularly given the conflicting results in studies of passive antibody therapy in the context of primary 327 maternal infection^{59,60}. While the dosing and frequency of hyperimmune globulin also differed in these 328 329 studies, a positive effect was only observed in women with very early infection, pointing to the potential 330 importance of accuracy in the dating of infection recency. Recent studies have started to explore the role that antibody responses play in CMV transmission in a rhesus macaque model^{61,62}. However, data in 331 humans is limited and often confounded by the differing risk of infection associated with primary as 332 compared to non-primary infection⁶³. Additionally, the panel of antigens tested in our investigation was not 333 334 exhaustive, and the reactivity patterns sometimes differed in association with different sequences, 335 conformational states, expression hosts, and other factors, the contributions and importance of which 336 have yet to be defined. These and other factors may represent worthwhile directions for a future study. 337 Overall, many open questions regarding the role of humoral immunity in the context of CMV 338 infection, transmission, latency, and reactivation remain. Higher resolution and more comprehensive 339 analysis of antibody responses using systems serology approaches has the potential to improve our

340 understanding of the complex virus-host interactions at play. Here, by analyzing highly curated cohorts,

- 341 we report and validate phenotypic signatures of gB, pentamer, and tegument-specific antibody responses
- that not only robustly classify primary infection status, but also provide insights into time of infection. It
- remains to be seen if the atypical dynamic profile of IgG3 responses to envelope glycoproteins elicited by
- 344 CMV is antigen-intrinsic and might be recapitulated when these antigens are delivered by other means, or
- if it may represent an evasion strategy dependent on other viral genes or aspects of the innate response
- to viral infection. In the meantime, this work stands to define novel hallmarks of primary CMV infection
- and time of infection that may present new opportunities to streamline primary infection diagnosis,
- 348 potentially impacting current clinical practice and enrolment of pregnant women with primary infection in
- interventional trials, thereby providing new insights into relative cCMV risk and management strategies.
- 350
- 351 Methods
- 352 Clinical Samples

353 Serum samples were gathered from subject cohort groups of pregnant primary infection, pregnant 354 latent infection, non-pregnant primary infection, non-pregnant latent infection, as well as CMV negative 355 patient cohort as a negative control group (Table 1). Human subjects were recruited from Fondazione 356 IRCCS Policlinico San Matteo, Pavia, Italy, and included healthy, primary, and latent CMV infected 357 subjects, as well as pregnant and non-pregnant subjects. An additional cohort of pregnant women with 358 primary infection was recruited from Erasme Hospital. Diagnosis of primary HCMV infection was based on 359 two or more of the following criteria: CMV-specific IgG seroconversion, CMV-specific IgM antibody 360 detection, low IgG avidity index and CMV DNAemia. Chronic infection was defined by the presence of 361 CMV-specific IgG and absence of CMV-specific IgM antibody, and no detection of CMV DNA in blood, 362 saliva, urine and genital secretion during pregnancy. In 89/114 (78%) pregnant women and 28/29 (95%) 363 non-pregnant subjects, onset of primary infection was defined by the appearance of symptoms, while in 364 19/114 (17%) asymptomatic pregnant women onset of infection was estimated on seroconversion (i.e. in 365 the mid between the last IgG negative and the first IgG positive result), occurring within a \leq 6-week 366 interval. Finally, in six asymptomatic pregnant women (5%) and one (3%) non-pregnant subject, onset of 367 infection was estimated on the kinetics of CMV-specific IgM and IgG avidity index. For a subgroup of 40 368 pregnant women and 28 non-pregnant subjects with primary infection, 2-4 sequential serum samples 369 collected until 6 months after onset of infection were available. Samples from pregnant women with 370 chronic infection were collected at 10, 20, and 30 weeks of gestation and at delivery. Sample collection 371 was approved by Fondazione IRCCS Policlinico San Matteo, and each participant gave written informed 372 consent.

373

374 Antibody Profiling Experiments

Fc receptors were expressed as previously described⁶⁴. A complete list of Fc detection reagents 375 376 and antigens used is provided in **Supplemental Table 1**. Pentamer and glycoprotein B were sourced 377 both commercially, through industry partners, and expressed in-house. For the latter, HCMV Pentamer 378 (UT, Towne strain) was produced by mixing plasmids encoding for residues 24 to 718 of gH with a Cterminal 6x HisTag, residues 31 to 278 of gL, residues 21 to 171 of UL128, residues 26 to 214 of UL130. 379 and residues 19 to 129 of UL131A, all with artificial signal sequences, at an equimolar ratio³¹. This 380 381 mixture was then used to transiently transfect FreeStyle293-F cells via polyethylenimine. Plasmids 382 encoding for postfusion HCMV gB (AD169 strain) residues 32-692 with an artificial N-terminal signal 383 sequence and a C-terminal HRV3C protease cleavage site, 8×HisTag, and a TwinStrep tag. One postfusion gB construct (UT, or JSM-1074) contained substitutions Y155G, I156H, Y157R, Y206H. 384 S238N, W240T, L241T, Y242H and C246S, which have been reported previously³⁰ and the other 385 construct (3p, or JSM-956) contained substitutions Y155G, I156H, Y157R, Y206H, W240A, L241T, 386 387 Y242H, C246S, R456A, R459G, M472P, R491P, G492P and a C-terminal T4 fibritin trimerization motif. 388 Plasmids were transiently transfected into FreeStyle 293-F cells via polyethylenimine. Pentamer was 389 purified using NiNTA resin (Thermo Scientific) and postfusion gB proteins were purified using Strep-Tactin

affinity resin (IBA Lifesciences). Affinity-purified proteins were further purified by size-exclusion

- 391 chromatography using a Superose6 10/300 column (Cytiva) in a buffer composed of 2 mM Tris pH 8.0,
- 392 200 mM NaCl, 0.02% NaN3.
- Characterization of antibody profiles was performed using the Fc array assay^{65,66}. Antigens were covalently coupled to magnetic microspheres (Luminex Corporation) using carbodiimide chemistry.
- 395 Serum dilutions used in assays ranged from 1:250-1:5000 based on initial pilot experiments and previous
- 396 experience. Detection of antigen specific antibodies was done using R-phycoerythrin-conjugated
- 397 secondary reagents specific to human immunoglobulin isotypes and subclasses and by Fc receptor
- tetramers. Median fluorescent intensity data was acquired on a FlexMap 3D array reader (Luminex
- 399 Corporation). Samples were run in technical duplicates and results were averaged.
- 400

401 Classification of CMV infection status

- 402 A binomial logistic regression model with least absolute shrinkage and selection operator (LASSO)
- regularization was used to prediction infection status. Model training was performed using the scikit-learn
- 404 (version 1.3) in Python (version 3.9) with default options. The regularization parameter was chosen using
- the option that gave the lowest classification error. Model accuracy was determined by the test set label
- 406 predictions compared with true labels. Accuracy was assessed over 100 repetitions of five-fold cross
- 407 validation. Permutation testing was done to measure model robustness by doing the same procedure as
- described but on randomly shuffled data. Feature importance was determined from a final model that
- 409 included all subjects.
- 410

411 Prediction of time since infection

- The same machine learning model as described for predicting CMV infection status was used, this time
- 413 minimizing mean squared error in time since infection. The model was trained on cross sectional data and
- 414 tested on all longitudinal samples.
- 415

416 Statistics

- 417 Statistical analysis was performed in GraphPad Prism (version 9.7). UMAP plots were generated in
- 418 Python (version 3.9) using the umap-learn package (version 0.4)⁶⁷ and then plotted using Prism. Volcano
- 419 plots were generated in R (version 4.3) using ggplot2. Statistical tests are described in the relevant figure
- 420 legends.
- 421

422 Study approval

- 423 The study was approved by the IRBs at Fondazione IRCCS Policlinico San Matteo and Erasme Hospital
- for sample collection, and Dartmouth College for sample testing and analysis.
- 425
- 426 Data availability

- 427 Data used in the study is available as **Supplemental Data File 1**.
- 428

429 Acknowledgements

- 430 This study was supported in part by Infect-ERA, GSK and Sanofi via the CYMAF consortium, as well as
- 431 by NIH U19AI45825. Pentamer and gB proteins were provided by GSK. A.M. is Research Director at the
- 432 F.R.S., FNRS, Belgium.
- 433

434 Conflict of Interest

- 435 A patent application for Systems and methods for identifying and treating primary and latent infections
- 436 and/or determining time since infection, WO2023154857A2, has been submitted by A.P.H, D. L., A.M,
- 437 and M.E.A..

438 References:

439	1	Cannon, M. J. & Davis, K. F. Washing our hands of the congenital cytomegalovirus disease
440		epidemic. BMC Public Health 5, 70 (2005). <u>https://doi.org:10.1186/1471-2458-5-70</u>
441	2	Schleiss, M. R. Congenital cytomegalovirus infection: molecular mechanisms mediating viral
442		pathogenesis. Infect Disord Drug Targets 11 , 449-465 (2011).
443		https://doi.org:10.2174/187152611797636721
444	3	Dietrich, M. L. & Schieffelin, J. S. Congenital Cytomegalovirus Infection. Ochsner J 19, 123-130
445		(2019). https://doi.org:10.31486/toj.18.0095
446	4	Pass, R. F. & Anderson, B. Mother-to-Child Transmission of Cytomegalovirus and Prevention of
447		Congenital Infection. J Pediatric Infect Dis Soc 3 Suppl 1 , S2-6 (2014).
448		https://doi.org:10.1093/jpids/piu069
449	5	Stagno, S. <i>et al.</i> Congenital cytomegalovirus infection: The relative importance of primary and
450		recurrent maternal infection. N Engl J Med 306 , 945-949 (1982).
451		https://doi.org:10.1056/nejm198204223061601
452	6	Lazzarotto, T. <i>et al.</i> Congenital Cytomegalovirus Infection: A Narrative Review of the Issues in
453		Screening and Management From a Panel of European Experts. Frontiers in Pediatrics 8 (2020).
454		https://doi.org:10.3389/fped.2020.00013
455	7	Simonazzi, G. <i>et al.</i> Perinatal Outcomes of Non-Primary Maternal Cytomegalovirus Infection: A
456		15-Year Experience. Fetal Diagn Ther 43 , 138-142 (2018). https://doi.org:10.1159/000477168
457	8	Gatta, L. A. <i>et al.</i> Clinical factors associated with cytomegalovirus shedding among seropositive
458		pregnant women. Am J Obstet Gynecol MFM 4, 100560 (2022).
459		https://doi.org:10.1016/j.ajogmf.2021.100560
460	9	Zelini, P. <i>et al.</i> Human cytomegalovirus non-primary infection during pregnancy: antibody
461		response, risk factors and newborn outcome. Clin Microbiol Infect 28 , 1375-1381 (2022).
462		https://doi.org:10.1016/j.cmi.2021.09.013
463	10	Kenneson, A. & Cannon, M. J. Review and meta-analysis of the epidemiology of congenital
464		cytomegalovirus (CMV) infection. Rev Med Virol 17, 253-276 (2007).
465		https://doi.org:10.1002/rmv.535
466	11	Revello, M. G. et al. A randomized trial of hyperimmune globulin to prevent congenital
467		cytomegalovirus. N Engl J Med 370, 1316-1326 (2014). https://doi.org:10.1056/NEJMoa1310214
468	12	Hughes, B. L. et al. A Trial of Hyperimmune Globulin to Prevent Congenital Cytomegalovirus
469		Infection. New England Journal of Medicine 385 , 436-444 (2021).
470		https://doi.org:10.1056/NEJMoa1913569
471	13	Kagan, K. O. et al. Outcome of pregnancies with recent primary cytomegalovirus infection in first
472		trimester treated with hyperimmunoglobulin: observational study. Ultrasound Obstet Gynecol
473		57, 560-567 (2021). https://doi.org:10.1002/uog.23596
474	14	Ross, S. A., Novak, Z., Pati, S. & Boppana, S. B. Overview of the diagnosis of cytomegalovirus
475		infection. Infect Disord Drug Targets 11, 466-474 (2011).
476		https://doi.org:10.2174/187152611797636703
477	15	Year 2007 position statement: Principles and guidelines for early hearing detection and
478		intervention programs. Pediatrics 120, 898-921 (2007). https://doi.org:10.1542/peds.2007-2333
479	16	Prince, H. E. & Lapé-Nixon, M. Role of cytomegalovirus (CMV) IgG avidity testing in diagnosing
480		primary CMV infection during pregnancy. Clin Vaccine Immunol 21, 1377-1384 (2014).
481		https://doi.org:10.1128/cvi.00487-14
482	17	Saldan, A. <i>et al.</i> Testing for Cytomegalovirus in Pregnancy. <i>Journal of Clinical Microbiology</i> 55,
483		693-702 (2017). https://doi.org:doi:10.1128/JCM.01868-16

484	18	Hughes, B. L. & Gyamfi-Bannerman, C. Diagnosis and antenatal management of congenital
485		cytomegalovirus infection. Am J Obstet Gynecol 214 , B5-b11 (2016).
486		https://doi.org:10.1016/j.ajog.2016.02.042
487	19	Abdullahi Nasir, I., Babayo, A. & Shehu, M. S. Clinical Significance of IgG Avidity Testing and
488		Other Considerations in the Diagnosis of Congenital Cytomegalovirus Infection: A Review
489		Update. <i>Medical Sciences</i> 4 , 5 (2016).
490	20	Chatzakis, C. et al. Timing of primary maternal cytomegalovirus infection and rates of vertical
491		transmission and fetal consequences. Am J Obstet Gynecol 223, 870-883.e811 (2020).
492		https://doi.org:10.1016/j.ajog.2020.05.038
493	21	Aghaeepour, N. <i>et al.</i> An immune clock of human pregnancy. <i>Science Immunology</i> 2 , eaan2946
494		(2017). https://doi.org:doi:10.1126/sciimmunol.aan2946
495	22	Zuniga, E. I., Macal, M., Lewis, G. M. & Harker, J. A. Innate and Adaptive Immune Regulation
496		During Chronic Viral Infections. Annu Rev Virol 2, 573-597 (2015).
497		https://doi.org:10.1146/annurev-virology-100114-055226
498	23	Rouse, B. T. & Sehrawat, S. Immunity and immunopathology to viruses: what decides the
499		outcome? Nat Rev Immunol 10, 514-526 (2010). https://doi.org:10.1038/nri2802
500	24	Ovies, C., Semmes, E. C. & Coyne, C. B. Pregnancy influences immune responses to SARS-CoV-2.
501		Science Translational Medicine 13 , eabm2070 (2021).
502		https://doi.org:doi:10.1126/scitransImed.abm2070
503	25	Steinhoff, M. C. <i>et al.</i> Influenza Immunization in Pregnancy — Antibody Responses in Mothers
504		and Infants. New England Journal of Medicine 362 , 1644-1646 (2010).
505		https://doi.org:10.1056/NEJMc0912599
506	26	Atyeo, C. G. <i>et al.</i> Maternal immune response and placental antibody transfer after COVID-19
507		vaccination across trimester and platforms. <i>Nature Communications</i> 13 , 3571 (2022).
508		https://doi.org:10.1038/s41467-022-31169-8
509	27	Ripalti, A. <i>et al.</i> Construction of polyepitope fusion antigens of human cytomegalovirus ppUL32:
510		reactivity with human antibodies. <i>Journal of clinical microbiology</i> 32 , 358-363 (1994).
511		https://doi.org:10.1128/icm.32.2.358-363.1994
512	28	Chandramouli, S. <i>et al.</i> Structure of HCMV glycoprotein B in the postfusion conformation bound
513		to a neutralizing human antibody. <i>Nat Commun</i> 6 , 8176 (2015).
514		https://doi.org:10.1038/ncomms9176
515	29	Chandramouli S <i>et al.</i> Structural basis for potent antibody-mediated neutralization of human
516	20	cytomegalovirus Sci Immunol 2 (2017) https://doi.org/10.1126/sciimmunol.aan1457
517	30	Ye X et al. Recognition of a highly conserved glycoprotein B enitope by a bivalent antibody
518	50	neutralizing HCMV at a nost-attachment sten. <i>PLoS Pathoa</i> 16 , e1008736 (2020)
519		https://doi.org/10.1371/journal.ppat.1008736
520	31	Wrann D et al. Structural basis for HCMV Pentamer recognition by neuronilin 2 and neutralizing
520	51	antibodies Sci Adv 8 eabm2546 (2022) https://doi.org/10.1126/sciadv.abm2546
521	32	Nachbagauer R <i>et al</i> Age Dependence and Isotype Specificity of Influenza Virus Hemagglutinin
522	52	Stalk-Reactive Antibodies in Humans, $mBio 7$ 10 1128/mbio 01996-01915 (2016)
523		https://doi.org/doi:10.1128/mbio.01996-15
525	22	Vates N L et al Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications
525	55	for detection of incident HIV infection <i>Aids</i> 25 2089-2097 (2011)
520		https://doi.org/10.1097/0AD.0b013e32834b348e
522	34	Doerr H. W. Rentschler M. & Scheifler G. Serologic detection of active infections with human
520	57	hernes viruses (CMV_ERV_HSV_VZV): Diagnostic notential of IgA class and IgG subclass specific
530		antibodies Infection 15 93-98 (1987) https://doi.org/10.1007/RE01650204
550		

531	35	Gilljam, G. & Wahren, B. Properties of IgG subclasses to human cytomegalovirus. J Virol Methods
532		25 , 139-151 (1989). <u>https://doi.org:10.1016/0166-0934(89)90028-1</u>
533	36	Gupta, C. K., Leszczynski, J., Gupta, R. K. & Siber, G. R. IgG subclass antibodies to human
534		cytomegalovirus (CMV) in normal human plasma samples and immune globulins and their
535		neutralizing activities. Biologicals 24, 117-124 (1996). https://doi.org:10.1006/biol.1996.0015
536	37	Joassin, L., Somze, A. & Reginster, M. Detection by enzyme-linked immunosorbent assay of
537		specific immunoglobulin G isotypes in primary and established cytomegalovirus infections.
538		Journal of Clinical Microbiology 27 , 139-144 (1989). <u>https://doi.org:doi:10.1128/jcm.27.1.139-</u>
539		<u>144.1989</u>
540	38	Rodriguez, G. E. & Adler, S. P. Immunoglobulin G subclass responses to cytomegalovirus in
541		seropositive patients after transfusion. <i>Transfusion</i> 30 , 528-531 (1990).
542		<u>https://doi.org:https://doi.org/10.1046/j.1537-2995.1990.30690333484.x</u>
543	39	Powers, C., DeFilippis, V., Malouli, D. & Früh, K. Cytomegalovirus immune evasion. Curr Top
544		Microbiol Immunol 325 , 333-359 (2008). <u>https://doi.org:10.1007/978-3-540-77349-8_19</u>
545	40	Jackson, S. E. et al. CMV immune evasion and manipulation of the immune system with aging.
546		Geroscience 39 , 273-291 (2017). <u>https://doi.org:10.1007/s11357-017-9986-6</u>
547	41	Genser, B., Truschnig-Wilders, M., Stünzner, D., Landini, M. P. & Halwachs-Baumann, G.
548		Evaluation of five commercial enzyme immunoassays for the detection of human
549		cytomegalovirus-specific IgM antibodies in the absence of a commercially available gold
550		standard. <i>Clin Chem Lab Med</i> 39 , 62-70 (2001). <u>https://doi.org:10.1515/cclm.2001.014</u>
551	42	Rasmussen, L. <i>et al.</i> Virus-specific IgG and IgM antibodies in normal and immunocompromised
552		subjects infected with cytomegalovirus. <i>J Infect Dis</i> 145 , 191-199 (1982).
553		https://doi.org:10.1093/infdis/145.2.191
554	43	Naumnik, B. et al. Comparison of serology assays and polymerase chain reaction for the
555		monitoring of active cytomegalovirus infection in renal transplant recipients. Transplant Proc 39,
556		2748-2750 (2007). <u>https://doi.org:10.1016/j.transproceed.2007.08.040</u>
557	44	Razonable, R. R. <i>et al.</i> Clinical Diagnostic Testing for Human Cytomegalovirus Infections. <i>J Infect</i>
558		Dis 221 , S74-s85 (2020). <u>https://doi.org:10.1093/infdis/jiz601</u>
559	45	Revello, M. G. <i>et al.</i> Comparative evaluation of eight commercial human cytomegalovirus lgG
560		avidity assays. <i>J Clin Virol</i> 48 , 255-259 (2010). <u>https://doi.org:10.1016/j.jcv.2010.05.004</u>
561	46	Joassin, L., Somze, A. & Reginster, M. Detection by enzyme-linked immunosorbent assay of
562		specific immunoglobulin G isotypes in primary and established cytomegalovirus infections. J Clin
563		Microbiol 27, 139-144 (1989). https://doi.org:10.1128/jcm.27.1.139-144.1989
564	47	Dugast, AS. et al. Independent evolution of Fc- and Fab-mediated HIV-1-specific antiviral
565		antibody activity following acute infection. European Journal of Immunology 44, 2925-2937
566		(2014). https://doi.org:https://doi.org/10.1002/eji.201344305
567	48	Sadanand, S. et al. Temporal variation in HIV-specific IgG subclass antibodies during acute
568		infection differentiates spontaneous controllers from chronic progressors. AIDS 32, 443-450
569		(2018). https://doi.org:10.1097/qad.000000000001716
570	49	Damelang, T., Rogerson, S. J., Kent, S. J. & Chung, A. W. Role of IgG3 in Infectious Diseases.
571		Trends Immunol 40, 197-211 (2019). https://doi.org:10.1016/j.it.2019.01.005
572	50	Dauby, N. <i>et al.</i> Limited Effector Memory B-Cell Response to Envelope Glycoprotein B During
573		Primary Human Cytomegalovirus Infection. J Infect Dis 213 , 1642-1650 (2016).
574		https://doi.org:10.1093/infdis/jiv769
575	51	Corrales-Aguilar, E. <i>et al.</i> Human cytomegalovirus Fcy binding proteins gp34 and gp68
576		antagonize Fcy receptors I, II and III. <i>PLoS Pathog</i> 10 , e1004131 (2014).
577		https://doi.org:10.1371/journal.ppat.1004131

578	52	Atalay, R. et al. Identification and expression of human cytomegalovirus transcription units
579		coding for two distinct Fcgamma receptor homologs. <i>J Virol</i> 76 , 8596-8608 (2002).
580		https://doi.org:10.1128/jvi.76.17.8596-8608.2002
581	53	Antonsson, A. & Johansson, P. J. H. Binding of human and animal immunoglobulins to the IgG Fc
582		receptor induced by human cytomegalovirus. <i>J Gen Virol</i> 82 , 1137-1145 (2001).
583		https://doi.org:10.1099/0022-1317-82-5-1137
584	54	Vezzani, G. <i>et al.</i> Human immunoglobulins are transported to HCMV viral envelope by viral Fc
585		gamma receptors-dependent and independent mechanisms. Front Microbiol 13, 1106401
586		(2022). https://doi.org:10.3389/fmicb.2022.1106401
587	55	Ssentongo, P. et al. Congenital Cytomegalovirus Infection Burden and Epidemiologic Risk Factors
588		in Countries With Universal Screening: A Systematic Review and Meta-analysis. JAMA Network
589		<i>Open</i> 4 , e2120736-e2120736 (2021). <u>https://doi.org:10.1001/jamanetworkopen.2021.20736</u>
590	56	Wang, C., Zhang, X., Bialek, S. & Cannon, M. J. Attribution of congenital cytomegalovirus
591		infection to primary versus non-primary maternal infection. Clin Infect Dis 52, e11-13 (2011).
592		https://doi.org:10.1093/cid/ciq085
593	57	Picone, O. <i>et al.</i> A series of 238 cytomegalovirus primary infections during pregnancy:
594		description and outcome. Prenat Diagn 33, 751-758 (2013). https://doi.org:10.1002/pd.4118
595	58	Lazzarotto, T., Guerra, B., Gabrielli, L., Lanari, M. & Landini, M. P. Update on the prevention,
596		diagnosis and management of cytomegalovirus infection during pregnancy. Clin Microbiol Infect
597		17, 1285-1293 (2011). https://doi.org:10.1111/j.1469-0691.2011.03564.x
598	59	Nigro, G., Adler, S. P., La Torre, R. & Best, A. M. Passive Immunization during Pregnancy for
599		Congenital Cytomegalovirus Infection. New England Journal of Medicine 353, 1350-1362 (2005).
600		https://doi.org:10.1056/NEJMoa043337
601	60	Jückstock, J., Rothenburger, M., Friese, K. & Traunmüller, F. Passive Immunization against
602		Congenital Cytomegalovirus Infection: Current State of Knowledge. Pharmacology 95, 209-217
603		(2015). <u>https://doi.org:10.1159/000381626</u>
604	61	Gong, Y. et al. Mathematical Modeling of Rhesus Cytomegalovirus Transplacental Transmission
605		in Seronegative Rhesus Macaques. <i>Viruses</i> 15 , 2040 (2023).
606	62	Otero, C. E. et al. Relationship of maternal cytomegalovirus-specific antibody responses and viral
607		load to vertical transmission risk following primary maternal infection in a rhesus macaque
608		model. PLoS Pathog 19, e1011378 (2023). <u>https://doi.org:10.1371/journal.ppat.1011378</u>
609	63	Semmes, E. C. et al. ADCC-activating antibodies correlate with decreased risk of congenital
610		human cytomegalovirus transmission. <i>JCI Insight</i> 8 (2023).
611		https://doi.org:10.1172/jci.insight.167768
612	64	Boesch, A. W. et al. Highly parallel characterization of IgG Fc binding interactions. mAbs 6, 915-
613		927 (2014). <u>https://doi.org:10.4161/mabs.28808</u>
614	65	Brown, E. P. <i>et al.</i> Multiplexed Fc array for evaluation of antigen-specific antibody effector
615		profiles. J Immunol Methods 443 , 33-44 (2017). <u>https://doi.org:10.1016/j.jim.2017.01.010</u>
616	66	Brown, E. P. et al. Optimization and qualification of an Fc Array assay for assessments of
617		antibodies against HIV-1/SIV. <i>J Immunol Methods</i> 455 , 24-33 (2018).
618		https://doi.org:10.1016/j.jim.2018.01.013
619	67	McInnes, L., Healy, J. & Melville, J. Umap: Uniform manifold approximation and projection for
620		dimension reduction. arXiv preprint arXiv:1802.03426 (2018).
621		
~		

medRxiv preprint doi: https://doi.org/10.1101/2024.02.21.24303056; this version posted February 23, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.



Figure 1: Antibody features distinguish primary from Chronic CMV infection but not pregnancy status. A. Uniform manifold approximation (UMAP) biplot of antibody features excluding IgM. Distinct clusters of subjects with primary (blue) and chronic (green) infection but not pregnancy status (hollow and filled symbols) are observed. B. Volcano plot of each CMV-specific antibody feature assessed. Volcano plot represents the log₂ fold change (x-axis) against the $-\log_{10} p$ value (Mann Whitney test: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001). Antibody specificities (Antigen) are indicated by shape and Fc characteristics (Detection) indicated by color. C. IgM, IgA, and IgG binding to CMV antigens (further described in Supplemental Table 1). Data are the mean median fluorescent intensity (MFI) values of technical replicates. Solid red line indicates median.



Figure 2: IgG Subclasses display distinct profiles in primary and chronic infection depending on antigen specificity. A. Levels of gB-, pentamer-, and tegument-specific IgG1, IgG2, IgG3, and IgG4 antibodies in individual with primary (blue) or chronic (green) CMV infection. **B.** Scatterplot and fit lines of levels of (UT) pentamer-specific IgG1 and IgG3 responses by infection status. Pearson correlation coefficient (R_P) indicated in inset. **C.** Scatterplot and fit line of levels of (UT) pentamer-specific IgG1 (left) and IgG3 (right) versus (UT) pentamer-specific Fc_γRIIIaV-binding antibodies. Pearson correlation coefficient (R_P) indicated in inset. **D.** Pearson correlation coefficients (R_P) for each pentamer antigen tested across Fc_γR by infection status. Solid lines denote group medians; differences between groups were assessed by Mann-Whitney test (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p <0.0001); values presented are median fluorescent intensities (MFI).



Figure 3: Machine learning accurately predicts primary or chronic CMV infection status. A. Schematic overview of cross-validated machine learning workflow employing antibody profiling data to discriminate between primary and chronic infection status in discovery and validation cohorts. B. Prediction accuracy for 100 repeated 5-fold cross-validation runs on actual (black) and permuted (gray) class labels. C. Confusion matrix of predicted versus actual class labels in the median model for 5-fold cross validation. D. Class probabilities of each sample in the discovery set when evaluated as a test sample in the cross-validation run exhibiting median performance (left) and for the validation cohort using the final model (right). E. The identities and coefficients of the features making the largest positive (n=5) or negative (n=5) contributions to the final model. Solid lines denote group medians; differences between groups or conditions were assessed by Mann-Whitney test (*p < 0.05, **p < 0.01, ***p < 0.001, and ****p <0.0001).



Figure 4: Longitudinal models define a molecular clock of CMV primary infection. A. Analysis overview. The infection status classification model trained on the cross-sectional cohort was applied to longitudinal samples available from the validation cohort. **B.** Class probabilities of each sample in longitudinal cohort over sample collection visits for individuals with primary (blue) and chronic (green) infection. **C.** Scatterplot of class probabilities for subjects defined as having primary infection at visit 1 over time. **D.** Scatterplots of features employed by classification model to predict infection status over time in the longitudinal cohort. **E.** Analysis overview. Primary infection samples from the longitudinal cohort samples were used to train a regression model to predict time since infection (days post symptom onset) that was applied to the primary samples from the cross-sectional cohort. **F.** Scatterplot of model predictions of time since infection when primary samples used for predicting days post symptom onset. Data shows the measure of the predicted label and its closeness to the true label.

Table 1. Cohort characteristics

Values that were not available are listed as NA.

	Naive	Cross-sectional				Longitudinal		Erasme
		Pregnant Primary	Pregnant Chronic	Non-pregnant Primary	Non-pregnant Chronic	Primary	Chronic	Primary
Subject number	n=9	n=114	n=30	n=29	n=30	n=57	n=37	n=23
Median age (range), years	34(22-50)	33 (31-36)	34 (31-36)	38 (32-40)	48 (43-58)	36(26-73)	34(25-40)	31(28-40)
Sex (n, %)								
Female	5(55%)	113 (100%)	30 (100%)	12 (41%)	12 (40%)	44(77%)	37(100%)	23(100%)
Male	4(44%)	0 (0%)	0 (0%)	17 (59%)	18 (60%)	13(23%)	0(0%)	0(0%)
Viral load (range), DNA copies/mL	-	25 (0-200)	0	68 (25-255)	0	25(0-200)	0	NA
Median days since PCR+ or symptom onset (range)	-	41 (32-55)	-	26 (24-38)	-	35(18-66)	-	NA
Location	Belgium	Italy	Italy	Italy	Italy	Italy	Italy	Belgium
IRB	Brussels	San Matteo	San Matteo	San Matteo	San Matteo	San Matteo	San Matteo	Brussels